⌘K
t
On February 28, 2025, Hikma Pharmaceuticals PLC announced that seven Persons Discharging Managerial Responsibility (PDMRs), including the Executive Chairman and CEO, acquired a combined total of 122,846 ordinary shares at nil cost. These shares were received through the vesting or exercise of conditional awards under the company's Executive Incentive Plan. Separately, PDMR Susan Ringdal also sold 4,173 shares at £21.71 each on the same date, totalling £90,596.87, to cover tax obligations.
| Date | 4 Mar 2025 |
| Time | 11:16:20 |
| Category | Director/PDMR dealings |
| ID | 3056Z |
Hikma Pharmaceuticals PLC - EIP Vesting
LONDON, 4 March 2025: Hikma Pharmaceuticals PLC (LSE: HIK) (NasdaqDubai: HIK) ("Hikma") (LEI: 549300BNS685UXH4JI75) announces that the following Persons Discharging Managerial Responsibility ("PDMR") have received shares as a result of the vesting or exercise of their conditional share awards which were granted on 25 February 2022 under the 2014 Executive Incentive Plan ("EIP") Element C and on 17 March 2016 under the EIP Element B.
Notification and public disclosure of transactions by persons discharging managerial responsibilities
Said Darwazah
|
1 |
Details of the person discharging managerial responsibilities / person closely associated |
||
|
a) |
Name |
Said Darwazah |
|
|
2 |
Reason for the notification |
||
|
a) |
Position/status |
Executive Chairman |
|
|
b) |
Initial notification /Amendment |
Initial notification |
|
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||
|
a) |
Name |
Hikma Pharmaceuticals PLC |
|
|
b) |
LEI |
549300BNS685UXH4JI75 |
|
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
||
|
a) |
Description of the financial instrument, type of instrument and identification code |
Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083 |
|
|
b) |
Nature of the transaction |
Shares acquired from the vesting of conditional awards under the EIP Element C. All Shares were retained. |
|
|
c) |
Price(s) and volume(s) |
Price(s) |
Volume(s) |
|
Nil |
18,420 |
||
|
d) |
Aggregated information
|
Price(s): nil Volume(s): 18,420 |
|
|
e) |
Date of the transaction |
28 February 2025 |
|
|
f) |
Place of the transaction |
London Stock Exchange (XLON) |
|
Riad Mishlawi
|
1 |
Details of the person discharging managerial responsibilities / person closely associated |
||
|
a) |
Name |
Riad Mishlawi |
|
|
2 |
Reason for the notification |
||
|
a) |
Position/status |
Chief Executive Officer |
|
|
b) |
Initial notification /Amendment |
Initial notification |
|
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||
|
a) |
Name |
Hikma Pharmaceuticals PLC |
|
|
b) |
LEI |
549300BNS685UXH4JI75 |
|
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
||
|
a) |
Description of the financial instrument, type of instrument and identification code |
Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083 |
|
|
b) |
Nature of the transaction |
Shares acquired from the vesting of conditional awards under the EIP Element C and exercise of conditional awards under the EIP Element B. All Shares were retained. |
|
|
c) |
Price(s) and volume(s) |
Price(s) |
Volume(s) |
|
Nil |
EIP Award, Element C: 18,691 |
||
|
Nil |
EIP Award, Element B: 19,890 |
||
|
d) |
Aggregated information
|
Price(s): nil Volume(s): 38,581 |
|
|
e) |
Date of the transaction |
28 February 2025 |
|
|
f) |
Place of the transaction |
London Stock Exchange (XLON) |
|
Mazen Darwazah
|
1 |
Details of the person discharging managerial responsibilities / person closely associated |
||
|
a) |
Name |
Mazen Darwazah |
|
|
2 |
Reason for the notification |
||
|
a) |
Position/status |
Executive Vice Chairman |
|
|
b) |
Initial notification /Amendment |
Initial notification |
|
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||
|
a) |
Name |
Hikma Pharmaceuticals PLC |
|
|
b) |
LEI |
549300BNS685UXH4JI75 |
|
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
||
|
a) |
Description of the financial instrument, type of instrument and identification code |
Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083 |
|
|
b) |
Nature of the transaction |
Shares acquired from the vesting of conditional awards under the EIP Element C. All Shares were retained. |
|
|
c) |
Price(s) and volume(s) |
Price(s) |
Volume(s) |
|
Nil |
14,844 |
||
|
d) |
Aggregated information
|
Price(s): nil Volume(s): 14,844 |
|
|
e) |
Date of the transaction |
28 February 2025 |
|
|
f) |
Place of the transaction |
London Stock Exchange (XLON) |
|
Khalid Nabilsi
|
1 |
Details of the person discharging managerial responsibilities / person closely associated |
||
|
a) |
Name |
Khalid Nabilsi |
|
|
2 |
Reason for the notification |
||
|
a) |
Position/status |
PDMR |
|
|
b) |
Initial notification /Amendment |
Initial notification |
|
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||
|
a) |
Name |
Hikma Pharmaceuticals PLC |
|
|
b) |
LEI |
549300BNS685UXH4JI75 |
|
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
||
|
a) |
Description of the financial instrument, type of instrument and identification code |
Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083 |
|
|
b) |
Nature of the transaction |
Shares acquired from the vesting of conditional awards under the EIP Element C. All Shares were retained. |
|
|
c) |
Price(s) and volume(s) |
Price(s) |
Volume(s) |
|
Nil |
17,003 |
||
|
d) |
Aggregated information |
Price(s): nil Volume(s): 17,003 |
|
|
e) |
Date of the transaction |
28 February 2025 |
|
|
f) |
Place of the transaction |
London Stock Exchange (XLON) |
|
Bassam Kanaan
|
1 |
Details of the person discharging managerial responsibilities / person closely associated |
||
|
a) |
Name |
Bassam Kanaan |
|
|
2 |
Reason for the notification |
||
|
a) |
Position/status |
PDMR |
|
|
b) |
Initial notification /Amendment |
Initial notification |
|
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||
|
a) |
Name |
Hikma Pharmaceuticals PLC |
|
|
b) |
LEI |
549300BNS685UXH4JI75 |
|
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
||
|
a) |
Description of the financial instrument, type of instrument and identification code |
Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083 |
|
|
b) |
Nature of the transaction |
Shares acquired from the vesting of conditional awards under the EIP Element C. All Shares were retained. |
|
|
c) |
Price(s) and volume(s) |
Price(s) |
Volume(s) |
|
Nil |
16,472 |
||
|
d) |
Aggregated information |
Price(s): nil Volume(s): 16,472 |
|
|
e) |
Date of the transaction |
28 February 2025 |
|
|
f) |
Place of the transaction |
London Stock Exchange (XLON) |
|
Susan Ringdal
|
1 |
Details of the person discharging managerial responsibilities / person closely associated |
||
|
a) |
Name |
Susan Ringdal |
|
|
2 |
Reason for the notification |
||
|
a) |
Position/status |
PDMR |
|
|
b) |
Initial notification /Amendment |
Initial notification |
|
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||
|
a) |
Name |
Hikma Pharmaceuticals PLC |
|
|
b) |
LEI |
549300BNS685UXH4JI75 |
|
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
||
|
a) |
Description of the financial instrument, type of instrument and identification code |
Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083 |
|
|
b) |
Nature of the transaction |
Shares acquired from the vesting of conditional awards under the EIP Element C. |
|
|
c) |
Price(s) and volume(s) |
Price(s) |
Volume(s) |
|
Nil |
8,851 |
||
|
d) |
Aggregated information |
Price(s): nil Volume(s): 8,851 |
|
|
e) |
Date of the transaction |
28 February 2025 |
|
|
f) |
Place of the transaction |
London Stock Exchange (XLON) |
|
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
||
|
a) |
Description of the financial instrument, type of instrument and identification code |
Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083 |
|
|
b) |
Nature of the transaction |
Shares sold to cover tax following the vesting of conditional awards under the EIP Element C. |
|
|
c) |
Price(s) and volume(s) |
Price(s) |
Volume(s) |
|
£21.71 |
4,173 |
||
|
d) |
Aggregated information |
Price(s): £21.71 Volume(s): 4,173 Total(s): £90,596.87 |
|
|
e) |
Date of the transaction |
28 February 2025 |
|
|
f) |
Place of the transaction |
London Stock Exchange (XLON) |
|
Hussein Arkhagha
|
1 |
Details of the person discharging managerial responsibilities / person closely associated |
||
|
a) |
Name |
Hussein Arkhagha |
|
|
2 |
Reason for the notification |
||
|
a) |
Position/status |
PDMR |
|
|
b) |
Initial notification /Amendment |
Initial notification |
|
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||
|
a) |
Name |
Hikma Pharmaceuticals PLC |
|
|
b) |
LEI |
549300BNS685UXH4JI75 |
|
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
||
|
a) |
Description of the financial instrument, type of instrument and identification code |
Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083 |
|
|
b) |
Nature of the transaction |
Shares acquired from the vesting of conditional awards under the EIP Element C. All Shares were retained. |
|
|
c) |
Price(s) and volume(s) |
Price(s) |
Volume(s) |
|
Nil |
8,675 |
||
|
d) |
Aggregated information |
Price(s): nil Volume(s): 8,675 |
|
|
e) |
Date of the transaction |
28 February 2025 |
|
|
f) |
Place of the transaction |
London Stock Exchange (XLON) |
|
Helen Middlemist
Group Company Secretary
+44 (0)20 7399 2760
4 March 2025